{"entity":{"id":"nct06022861","kind":"trial","name":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma","aka":[],"tldr":"A phase 3 trial of Cisplatin and Nivolumab in oesophageal cancer, run by Shandong Boan Biotechnology Co., Ltd, now recruiting.","summary":"A Study to Compare the Efficacy and Safety of LY01015 and Opdivo® Combined Respectively With Chemotherapy in Advanced or Metastatic Esophageal Squamous Cell Carcinoma is a phase 3 interventional study registered as NCT06022861 by Shandong Boan Biotechnology Co., Ltd, with 510 participants planned, started 2023-10-12 and due to reach its primary completion in 2025-06. Interventions recorded: LY01015, Fluorouracil, Cisplatin and Opdivo®.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06022861","url":"https://clinicaltrials.gov/study/NCT06022861"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["esophageal","oesophageal-squamous-cell-carcinoma"],"sections":[],"technologies":["checkpoint-inhibitor","cytotoxic-chemotherapy","platinum"],"targets":[],"drugs":["cisplatin","nivolumab"],"companies":["luye-pharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT06022861","phase":"3","setting":"A Randomized, Double-blind, Multicenter, Phase 3 Study to Compare the Efficacy and Safety of LY01015 and Opdivo®（Nivolumab Injection）Combined Respectively With Fluorouracil Plus Cisplatin in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma.","sponsor":"Shandong Boan Biotechnology Co., Ltd","started":"2023-10-12","startedType":"actual","enrolled":510,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct06022861/","neighbours":{"cancer":[{"id":"esophageal","kind":"cancer","name":"Oesophageal cancer","route":"/cancers/esophageal/"},{"id":"oesophageal-squamous-cell-carcinoma","kind":"cancer","name":"Oesophageal squamous cell carcinoma","route":"/cancers/oesophageal-squamous-cell-carcinoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"},{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"},{"id":"platinum","kind":"technology","name":"Platinum agents","route":"/technologies/platinum/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"nivolumab","kind":"drug","name":"Nivolumab","route":"/drugs/nivolumab/"}],"company":[{"id":"luye-pharma","kind":"company","name":"Luye Pharma Group","route":"/companies/luye-pharma/"}]}}